ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2676

Is It Useful to Determine All Rheumatoid Factors Isotypes to Enhance Rheumatoid Arthritis Detection?  a Clinical Laboratory Perspective

Alejandro Garza-Alpirez1, Mario Alberto Garza-Elizondo2, David Vega-Morales2, Cassandra Skinner-Taylor2, Ricardo Ramírez3, Roberto Negrete-López4, Jorge Esquivel-Valerio2, Miguel Villarreal-Alarcon2 and Andrés Mendiola1, 1Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario " Dr. José Eleuterio González". Universidad Autónoma de Nuevo León, Monterrey, Mexico, 2Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Mexico, 3Rheumatology, Hospital Universitario, UANL., Monterrey, Mexico, 4Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario, Monterrey, Mexico

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: laboratory tests and rheumatoid arthritis (RA), Rheumatoid Factor

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Rheumatoid Arthritis - Clinical Aspects Poster Session III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis (RA) diagnosis includes determination of autoantibodies and, their presence can represents 33% (2/6) to 50% (3/6) of the 2010 ACR/EULAR classification criteria [1]. Rheumatoid factor has three isotypes, of which IgM is the most used because of its sensitivity and specificity [2]. The aim of this study is to evaluate the performance of RF isotypes alone and in combination with anti-cyclic citrullinated peptide (anti-CCP) antibodies in the RA diagnosis.

Methods: An observational, retrospective and analytical study was made. We selected all results of RF and anti-CCP sent to our laboratory between March 2014 and March 2015 with an inflammatory arthritis suspicion. We collected final diagnosis according to medical records and classified patients with RA (2010 ACR-EULAR), Osteoarthritis (OA, ACR), Systemic lupus erythematosus (SLE,1987 ACR criteria) and Primary Sjögren syndrome (pSS, 2012 American-European-Consensus-Group (CETA) criteria). RF isotypes evaluated was IgA, IgM and IgG measured by ELISA (ORGENTEC®) with a cut-off > 20 IU and anti-CCP2 antibodies by ELISA (ORGENTEC®) with a cut-off> 25 IU. We made a descriptive analysis of the seropositivity according to different diseases. Then, we performed an analysis of sensitivity and specificity using autoantibodies alone and in different combinations for the final RA diagnosis.

Results: We included 62 (44.3%) RA patients, 10 (7.1%) patients with SS, 5 (3.5%) patients with SLE, and 52 (37.1%) patients with OA. In table 1 we described autoantibodies frequencies according to different diseases. Sensitivity and specificity to RA diagnosis was represented in Table 2 with autoantibodies combinations.

Conclusion: The combination of the four autoantibodies increased sensitivity for RA detection, although we observed a decreased of global specificity of the test.

References: 1.Aletaha D, Neogi T, Silman AJ, et al. Arthritis Rheum 2010;62:2569-81. 2. Sun J, Zhang Y, Liu L, et al. Clin Exp Rheumatol 2014;32:11-21

Table 1. Frequencies of autoantibodies according different diseases

Test

     RA n, (%)  

    OA n, (%)  

    pSS n, (%)  

    SLE n, (%)  

IgM RF

     54 (62.8)

    12 (23.1)

      6 (66)

      3 (60)

IgA RF 

     46 (53.5)

      7 (13.5)

      3 (33.3)

      4 (7.8)

IgG RF 

     44 (51.2)

    10 (19.2)

      4 (44)

      1 (20)

anti-CCP

     43 (44)

     6 (11.5)

      5 (50)

      1 (20)

RA: Rheumatoid Arthritis, OA: Osteoarthritis, pSS: Primary Sjögren Syndrome, SLE: Systemic Lupus Erythematosus. RF: Rheumatoid Factor, anti-CCP: anti-Cyclic Citrullinated Peptide antibodies

Table 2. Sensitivity and specificity according to autoantibodies and their combinations for RA detection

Test

    Sensitivity (%)    

    Specificity (%)    

IgG RF

         49.4

          89.7

Anti-CCP

         49.4

          96.2

IgA RF

         54

          90.6

IgM RF

         62.1

          90.6

IgA+, IgG+

         65.1

          83

CCP+, IgA+

         66.3

          86.8

CCP+, IgG+

         67.4

          84.9

CCP+, IgM+

         68.6

          86.8

IgM+, IgG+

         69.8

          83

IgM+, IgA+

         72.1

          83

IgM+, IgA+, IgG+

         76.7

          77.4

IgM+, IgA+, IgG+, CCP+

         81.4

          73.6

RF: rheumatoid factor, Anti-CCP: anti-cyclic citrullinated peptide antibodies


Disclosure: A. Garza-Alpirez, None; M. A. Garza-Elizondo, None; D. Vega-Morales, None; C. Skinner-Taylor, None; R. Ramírez, None; R. Negrete-López, None; J. Esquivel-Valerio, None; M. Villarreal-Alarcon, None; A. Mendiola, None.

To cite this abstract in AMA style:

Garza-Alpirez A, Garza-Elizondo MA, Vega-Morales D, Skinner-Taylor C, Ramírez R, Negrete-López R, Esquivel-Valerio J, Villarreal-Alarcon M, Mendiola A. Is It Useful to Determine All Rheumatoid Factors Isotypes to Enhance Rheumatoid Arthritis Detection?  a Clinical Laboratory Perspective [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/is-it-useful-to-determine-all-rheumatoid-factors-isotypes-to-enhance-rheumatoid-arthritis-detection-a-clinical-laboratory-perspective/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/is-it-useful-to-determine-all-rheumatoid-factors-isotypes-to-enhance-rheumatoid-arthritis-detection-a-clinical-laboratory-perspective/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology